Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1984 18
1985 61
1986 52
1987 122
1988 93
1989 112
1990 147
1991 131
1992 118
1993 157
1994 178
1995 183
1996 128
1997 165
1998 144
1999 173
2000 190
2001 200
2002 243
2003 238
2004 299
2005 305
2006 369
2007 470
2008 559
2009 604
2010 661
2011 712
2012 713
2013 798
2014 858
2015 848
2016 837
2017 800
2018 741
2019 767
2020 882
2021 952
2022 924
2023 895
2024 498

Search Results

15,277 results

Results by year

Filters applied: . Clear all
Page 1
Renal cell carcinoma.
Merseburger AS, Ljungberg B, Bex A. Merseburger AS, et al. World J Urol. 2016 Aug;34(8):1051-2. doi: 10.1007/s00345-016-1892-5. World J Urol. 2016. PMID: 27401325 Free article. No abstract available.
Renal cell carcinoma.
Rini BI, Campbell SC, Escudier B. Rini BI, et al. Lancet. 2009 Mar 28;373(9669):1119-32. doi: 10.1016/S0140-6736(09)60229-4. Epub 2009 Mar 5. Lancet. 2009. PMID: 19269025 Free article. Review.
Renal cell carcinoma.
Choueiri TK. Choueiri TK. Hematol Oncol Clin North Am. 2011 Aug;25(4):xiii-xiv. doi: 10.1016/j.hoc.2011.06.001. Hematol Oncol Clin North Am. 2011. PMID: 21763960 No abstract available.
Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial.
Albiges L, Gurney H, Atduev V, Suarez C, Climent MA, Pook D, Tomczak P, Barthelemy P, Lee JL, Stus V, Ferguson T, Wiechno P, Gokmen E, Lacombe L, Gedye C, Perini RF, Sharma M, Peng X, Lee CH. Albiges L, et al. Lancet Oncol. 2023 Aug;24(8):881-891. doi: 10.1016/S1470-2045(23)00276-0. Epub 2023 Jul 11. Lancet Oncol. 2023. PMID: 37451291 Clinical Trial.
Approaches to Oligometastatic Renal Cell Carcinoma.
Magne N, Milhade N, Sargos P, Bouleftour W. Magne N, et al. Curr Oncol Rep. 2023 Apr;25(4):251-256. doi: 10.1007/s11912-023-01379-4. Epub 2023 Feb 18. Curr Oncol Rep. 2023. PMID: 36808558 Review.
Renal-cell carcinoma.
Doh L, Curtis AE, Teh BS. Doh L, et al. N Engl J Med. 2006 Mar 9;354(10):1095-6; author reply 1095-6. doi: 10.1056/NEJMc053645. N Engl J Med. 2006. PMID: 16525153 No abstract available.
Immunotherapy for renal cell carcinoma.
Sheng IY, Rini BI. Sheng IY, et al. Expert Opin Biol Ther. 2019 Sep;19(9):897-905. doi: 10.1080/14712598.2019.1628946. Epub 2019 Jun 12. Expert Opin Biol Ther. 2019. PMID: 31173514 Review.
Renal cell carcinoma.
Savage PD. Savage PD. Curr Opin Oncol. 1994 May;6(3):301-7. doi: 10.1097/00001622-199405000-00013. Curr Opin Oncol. 1994. PMID: 8080860 Review.
Immunomodulatory Therapies for Renal Cell Carcinoma.
Liu M, Wu H, Shangguan D, Jiang Y, Li X, Liu S, Zhou B, Yin T, Gong Z. Liu M, et al. Protein Pept Lett. 2018;25(6):534-547. doi: 10.2174/0929866525666180531080118. Protein Pept Lett. 2018. PMID: 29848257 Review.
15,277 results
You have reached the last available page of results. Please see the User Guide for more information.